New therapies for Parkinson's disease targeting a specific receptor
Parkinson's disease therapies targeting GUCY2C
This study is looking at a new way to help people with Parkinson's disease by focusing on a special receptor that could protect important brain cells from damage, with the hope of creating treatments that not only ease symptoms but also slow down the disease.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10904970 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating Parkinson's disease by targeting the guanylyl cyclase C (GUCY2C) receptor, which plays a role in protecting neurons from degeneration. The study aims to understand how this receptor can be leveraged to prevent the loss of dopaminergic neurons, which is crucial for managing the symptoms of Parkinson's disease. By exploring the gut-brain connection and its impact on neuronal health, the research seeks to develop therapies that not only alleviate symptoms but also slow disease progression. Patients may be involved in trials that assess the effectiveness of these new therapies in improving their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease who are experiencing motor dysfunction and cognitive decline.
Not a fit: Patients with Parkinson's disease who are in advanced stages of the disease or those who do not respond to current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow the progression of Parkinson's disease and improve quality of life for patients.
How similar studies have performed: While the approach of targeting GUCY2C in the context of Parkinson's disease is relatively novel, similar strategies targeting gut-brain interactions have shown promise in other neurological conditions.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Cheslow, Lara — Thomas Jefferson University
- Study coordinator: Cheslow, Lara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.